Octavian Andronic1, Yvonne Achermann2, Thorsten Jentzsch3, Flurin Bearth4, Andreas Schweizer3, Karl Wieser3, Sandro F Fucentese3, Stefan Rahm3, Annelies S Zinkernagel2, Patrick O Zingg3. 1. Department of Orthopaedics, Balgrist University Hospital, University of Zurich, Forchstrasse 340, 8008, Zurich, Switzerland. octavian.andronic@balgrist.ch. 2. Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland. 3. Department of Orthopaedics, Balgrist University Hospital, University of Zurich, Forchstrasse 340, 8008, Zurich, Switzerland. 4. University of Zurich, Rämistrasse 71, 8006, Zürich, Switzerland.
Abstract
PURPOSE: To report and analyse factors affecting the outcome of streptococcal periprosthetic joint infections (PJIs). METHODS: A retrospective analysis of consecutive streptococcal PJIs was performed. Musculoskeletal Infection Society 2013 criteria were used. Outcome was compared with a prospective PJI cohort from the same institution. RESULTS: The most common isolated streptococcal species was Streptococcus dysgalactiae (9/22, 41%) among 22 patients included. Surgical treatment consisted of DAIR (debridement, antibiotics, irrigation and retention) in 12 (55%), one-stage revision arthroplasty in one (4%), two-stage revision arthroplasty in eight (37%) and implant removal in one (4%) patient. An infection free-outcome was achieved in 15 cases (68%), whilst seven (32%) patients failed initial revision and relapsed with the same pathogen, from which six were treated with DAIR and one with one-stage revision arthroplasty. No failures were observed in patients who received a two-stage revision. Failure rates did not differ in the cases treated with rifampin (1/5) from those without 6/17 (p = 0.55). There was no correlation between the length of antibiotic treatment and relapse (p = 0.723). In all failures, a persistent distant infection focus was identified at the time of relapse. Compared with our prospective PJI cohort, relapse rates were significantly higher 32% vs 12% (p < 0.05). CONCLUSION: No correlation with the use of rifampin or length of antibiotic treatment was found. No failures were observed in patients who received a two-stage revision, which may be the surgical treatment of choice. A distant persisting infection focus could be the reason for PJI relapse with recurrent hematogenous seeding in the joint.
PURPOSE: To report and analyse factors affecting the outcome of streptococcal periprosthetic joint infections (PJIs). METHODS: A retrospective analysis of consecutive streptococcal PJIs was performed. Musculoskeletal Infection Society 2013 criteria were used. Outcome was compared with a prospective PJI cohort from the same institution. RESULTS: The most common isolated streptococcal species was Streptococcus dysgalactiae (9/22, 41%) among 22 patients included. Surgical treatment consisted of DAIR (debridement, antibiotics, irrigation and retention) in 12 (55%), one-stage revision arthroplasty in one (4%), two-stage revision arthroplasty in eight (37%) and implant removal in one (4%) patient. An infection free-outcome was achieved in 15 cases (68%), whilst seven (32%) patients failed initial revision and relapsed with the same pathogen, from which six were treated with DAIR and one with one-stage revision arthroplasty. No failures were observed in patients who received a two-stage revision. Failure rates did not differ in the cases treated with rifampin (1/5) from those without 6/17 (p = 0.55). There was no correlation between the length of antibiotic treatment and relapse (p = 0.723). In all failures, a persistent distant infection focus was identified at the time of relapse. Compared with our prospective PJI cohort, relapse rates were significantly higher 32% vs 12% (p < 0.05). CONCLUSION: No correlation with the use of rifampin or length of antibiotic treatment was found. No failures were observed in patients who received a two-stage revision, which may be the surgical treatment of choice. A distant persisting infection focus could be the reason for PJI relapse with recurrent hematogenous seeding in the joint.
Authors: Javad Parvizi; Benjamin Zmistowski; Elie F Berbari; Thomas W Bauer; Bryan D Springer; Craig J Della Valle; Kevin L Garvin; Michael A Mont; Montri D Wongworawat; Charalampos G Zalavras Journal: Clin Orthop Relat Res Date: 2011-11 Impact factor: 4.176
Authors: Venkat Boddapati; Michael C Fu; David J Mayman; Edwin P Su; Peter K Sculco; Alexander S McLawhorn Journal: J Arthroplasty Date: 2017-09-23 Impact factor: 4.757
Authors: Jaime Lora-Tamayo; Éric Senneville; Alba Ribera; Louis Bernard; Michel Dupon; Valérie Zeller; Ho Kwong Li; Cédric Arvieux; Martin Clauss; Ilker Uçkay; Dace Vigante; Tristan Ferry; José Antonio Iribarren; Trisha N Peel; Parham Sendi; Nina Gorišek Miksic; Dolors Rodríguez-Pardo; María Dolores Del Toro; Marta Fernández-Sampedro; Ulrike Dapunt; Kaisa Huotari; Joshua S Davis; Julián Palomino; Danielle Neut; Benjamin M Clark; Thomas Gottlieb; Rihard Trebše; Alex Soriano; Alberto Bahamonde; Laura Guío; Alicia Rico; Mauro J C Salles; M José G Pais; Natividad Benito; Melchor Riera; Lucía Gómez; Craig A Aboltins; Jaime Esteban; Juan Pablo Horcajada; Karina O'Connell; Matteo Ferrari; Gábor Skaliczki; Rafael San Juan; Javier Cobo; Mar Sánchez-Somolinos; Antonio Ramos; Efthymia Giannitsioti; Alfredo Jover-Sáenz; Josu Mirena Baraia-Etxaburu; José María Barbero; Peter F M Choong; Nathalie Asseray; Séverine Ansart; Gwenäel Le Moal; Werner Zimmerli; Javier Ariza Journal: Clin Infect Dis Date: 2017-06-15 Impact factor: 9.079
Authors: E Fiaux; M Titecat; O Robineau; J Lora-Tamayo; Y El Samad; M Etienne; N Frebourg; N Blondiaux; B Brunschweiler; F Dujardin; E Beltrand; C Loiez; V Cattoir; J P Canarelli; C Hulet; M Valette; S Nguyen; F Caron; H Migaud; E Senneville Journal: BMC Infect Dis Date: 2016-10-13 Impact factor: 3.090
Authors: Mariana Albano; Melissa J Karau; Kerryl E Greenwood-Quaintance; Douglas R Osmon; Caitlin P Oravec; Daniel J Berry; Matthew P Abdel; Robin Patel Journal: Microbiol Spectr Date: 2021-07-14